Intestine Segment to Lead Organoids Market During 2023–2031

According to our new research study on “Organoids Market  Forecast to 2031 –Global Analysis – by Type, Application, Source, and Geography,” the market size is expected to grow from US$ 3.03 billion in 2023 to US$ 15.01 billion by 2031; it is projected to register a CAGR of 22.1% during 2023–2031. The organoids market  growth is attributed to the increasing demand for innovative drug screening services and a surge in the popularity of personalized drugs. Key developments by companies are likely to offer opportunities for market growth. However, the dearth of skilled professionals hinders the market progress.

Organoids are stem cell-derived, microscopic, self-organizing three-dimensional tissue cultures. These cultures can be designed to express certain features of an organ, such as the production of only particular cell types, or to mimic a significant portion of its complexity. Organoids are developed from stem cells, which are unbounded multiplicity cells that give rise to a variety of cell types in their offspring. To allow stem cells to follow their own genetic fate and self-organize into tiny structures that resemble miniature organs, scientists have learned how to provide the correct conditions for the stem cells. Organoids can be as small as 5 mm, or they can be smaller than the breadth of a hair. The organoids market  report emphasizes key factors impacting the market and showcases the developments of prominent players.

Based on type, the Organoids Market  is classified into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held the largest organoids market  share in 2023; it is estimated to register the highest CAGR during 2023–2031. Intestinal organoids are 3D models of the human intestinal epithelium that can be utilized in patient-specific in vitro research to investigate the properties of the intestinal epithelium. The prevalence of inflammatory bowel diseases (IBD) is rapidly increasing across developed and developing countries. IBDs such as Crohn's disease and ulcerative colitis are common worldwide. According to data by the European Federation of Crohn's & Ulcerative Colitis Association (EFCCA), published in May 2022, ~10 million people across the world live with IBDs. The data also stated that Crohn's disease or ulcerative colitis was common in the UK in 2022, with a rate of 1 in every 123 people. In terms of source, the organoids market  is bifurcated into pluripotent stem cells and organ-specific adult stem cells.

Based on application, the market is segmented into developmental biology, infectious disease pathology, regenerative medicine, drug toxicity & efficacy testing, drug discovery & personalized medicine, and others. The developmental biology disease segment held the largest organoids market  share in 2023, and it is estimated to register the highest CAGR during 2023–2031. Developmental biology is the study of processes involved in the growth and development of multicellular organisms, which are controlled by their genes. Organoids developed from stem cells or tissues in culture can be converted into structures that resemble the in vivo anatomy and physiology of intact organs. Human organoid cultures can be used to study human development and model diseases with the same depth of analysis that is customary for research with nonhuman model organisms. Technological advancements in 3D bioprinting have shown a massive potential to facilitate organ development, as the time required for organoid culturing is much less than traditional tissue culture methods. Patient-derived human organoid studies may create new opportunities in the fields of tissue engineering and regenerative medicine, generating knowledge and tools for preclinical testing in drug development studies.

The organoids market, by source, is segregated into pluripotent stem cells and organ-specific adult stem cells. The pluripotent stem cells segment held the largest share in the organoids market in 2023. The organoids market, by offerings, is segregated into instruments, consumables, and services. Instruments segment is further divided into devices and equipment. On the other hand, consumables segment is divided into sensors and others. The consumables segment held the largest share in the organoids market in 2023. The organoids market, by method, is segregated into hanging drop, micropatterned plates, ultralow attachment plates, microdroplet/emulsion, and others. The hanging drop segment held the largest share in the organoids market in 2023.

Integration of Artificial Intelligence to Bring New Trends in Market in Coming Years

Artificial intelligence (AI) integration is set to be a transformative force in the organoid market, driving a chain of innovation and unlocking new possibilities in research, drug development, and personalized medicine. AI has the potential to play a critical role in enhancing the efficiency, accuracy, and impact of organoid-based technologies, ushering in a new era of personalized healthcare. AI algorithms can analyze vast datasets generated by organoid experiments, identifying patterns, predicting outcomes, and generating insights that may not be possible through manual efforts. This can accelerate drug discovery by identifying promising drug candidates, optimizing treatment regimens based on individual patient responses, and predicting potential side effects. AI-powered analysis can also optimize organoid production processes, enhancing consistency, scalability, and quality control. Furthermore, AI-driven automation can revolutionize organoid production and research workflows. Thus, the integration of artificial intelligence is likely to bring new organoids market  trends in the coming years.

Key players identified and evaluated while performing organoids market  analysis are Sino Biological Inc., Eurofins Scientific SE, Molecular Devices, LLC., InSphero, Cyprio, InnoSer, LABTOO, CUSABIO TECHNOLOGY LLC, Oncodesign Services, and HUB Organoids B.V. (Hubrecht Organoid Technology).

The geographic scope of the organoids market  report encompasses North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). North America held the largest share of the market in 2023. The organoids market  size in North America is expected to register a CAGR of 21.9% during 2023–2031. The market in Asia Pacific is expected to record the highest CAGR during the forecast period. The projected market growth in the region during the forecast period is attributed to factors such as the increasing use of organoids, government efforts to raise awareness related to human organoids, supportive regulations for the development and commercialization of advanced human organoid products, and an upsurge in the funding for organoid research.

Contact Us

Contact Person: Sameer Joshi

Phone: +1-646-491-9876

Email Id: sales@premiummarketinsights.com